Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech ca.finance.yahoo.com/news/bi…

$EQ First Subject Dosed in Phase 1 Trial of EQ504 Topline Phase 1 data anticipated in Q2'27 Triggers Milestone Closing of $20M. Co to sell 14.95M shares at $0.57/share and 20M pre-funded warrants at $0.56/per warrant

$MIRM Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva businesswire.com/news/home/2…

$CORT Reports Positive Results from Phase 2 BELLA Trial of Lifyorli Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer businesswire.com/news/home/2…

$MRNA PT raised to $230 from $167 at Piper

$ORKA CC at 8 am to report Wk 16 data for ORKA-001 from the ongoing EVERLAST-B trial on Monday

$SMMT Ivonescimab Plus Chemotherapy Demonstrates OS Superiority Compared to Durvalumab Plus Chemo in Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study. #ESMO26 Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 25% Compared to Durvalumab Plus Chemotherapy; OS Hazard Ratio 0.75 businesswire.com/news/home/2…

$GMAB Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful ORR in Patients with Metastatic Colorectal Cancer. #ESMO26 businesswire.com/news/home/2…

$AGEN Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at #ESMO26 businesswire.com/news/home/2…

$MRNA Investors Should Brace for More Whiplash Even after its sharp fall, the drugmaker’s stock price assumes wild successes wsj.com/health/pharma/modern…

$ZYME Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at #ESMO26 cORR of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer ir.zymeworks.com/news-releas…

$CATX halt

$RVMD Presents OS Data for RASONQUE Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at #ESMO26 $TNGX The subgroup analyses showed RASONQUE consistently provided an OS benefit across key subgroups, including patients with no identified tumor RAS mutation​ globenewswire.com/news-relea…

$ZLAB Zocilurtatug Pelitecan Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer businesswire.com/news/home/2…

$TNGX Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer. $RVMD 82% ORR, median PFS not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib ir.tangotx.com/news-releases…

$MRNA Citi reiterates Sell rating, PT $80

$ZYME Enters into a Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3. $RHHBY Zymeworks to receive $55M upfront and a $40M payment upon initiation of the Phase 1b trial ir.zymeworks.com/news-releas…

$ZLAB $250M PIPE at $22.04/ADS The financing is led by TCGX and includes participation from ADAR1 Capital, Balyasny Asset Management, Cormorant, Frazier Life Sciences, RA Capital, RTW Investments, Sirenia Capital, Wellington Management and Woodline Partners

$MRNA drop reflects high bar, not bad data - Mizuho’s Jared Holz cnbc.com/video/2026/10/22/mi…